These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 12434968)

  • 21. Cost utility of drugs for multiple sclerosis. Analysis goes too far.
    Ellis SJ
    BMJ; 2000 May; 320(7247):1475-6. PubMed ID: 10877571
    [No Abstract]   [Full Text] [Related]  

  • 22. [Drug therapy of multiple sclerosis].
    Kinnunen E
    Duodecim; 1999; 115(4):403-7. PubMed ID: 11830889
    [No Abstract]   [Full Text] [Related]  

  • 23. [Side-effects of the treatment with disease modifying drugs in patients with multiple sclerosis: an analysis of register data in the Yaroslavl region].
    Spirin NN; Kasatkin DS; Stepanov IO; Shipova EG; Baranova NS
    Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(8):27-33. PubMed ID: 23096035
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The value of economic modeling studies in the evaluation of treatment strategies for multiple sclerosis.
    Detournay B
    Value Health; 2002; 5(1):1-2. PubMed ID: 11873378
    [No Abstract]   [Full Text] [Related]  

  • 25. Glatiramer acetate (Copaxone) therapy induces CD8(+) T cell responses in patients with multiple sclerosis.
    Karandikar NJ; Crawford MP; Yan X; Ratts RB; Brenchley JM; Ambrozak DR; Lovett-Racke AE; Frohman EM; Stastny P; Douek DC; Koup RA; Racke MK
    J Clin Invest; 2002 Mar; 109(5):641-9. PubMed ID: 11877472
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Current concepts on the use of some immunomodulatory drugs in the treatment of multiple sclerosis].
    Correale J; Cristiano E
    Medicina (B Aires); 2001; 61(4):470-80. PubMed ID: 11563177
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [New therapeutic methods in the treatment of multiple sclerosis].
    Nervenarzt; 1996 Nov; 67(11 Suppl Neue Ther):1-12. PubMed ID: 9402424
    [No Abstract]   [Full Text] [Related]  

  • 28. The effectiveness of glatiramer acetate in clinical practice: an observational study.
    Fernández-Fernández Ó; Garcia-Trujillo L; Guerrero-Fernández M; León A; López-Madrona JC; Alonso A; Bustamante R; Fernández-Sánchez VE
    Rev Neurol; 2012 Jan; 54(1):1-9. PubMed ID: 22187206
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predictors of adherence to glatiramer acetate therapy in individuals with self-reported progressive forms of multiple sclerosis.
    Fraser C; Hadjimichael O; Vollmer T
    J Neurosci Nurs; 2003 Jun; 35(3):163-70. PubMed ID: 12830664
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. 1998 [classical article].
    Johnson KP; Brooks BR; Cohen JA; Ford CC; Goldstein J; Lisak RP; Myers LW; Panitch HS; Rose JW; Schiffer RB; Vollmer T; Weiner LP; Wolinsky JS;
    Neurology; 2001 Dec; 57(12 Suppl 5):S46-53. PubMed ID: 11902595
    [No Abstract]   [Full Text] [Related]  

  • 31. [Glatiramer acetate (Copaxone) influence on different stages of multiple sclerosis pathogenesis].
    Shmidt TE; Zhuchenko TD; Iakhno NN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2003; (Spec No 2):79-82. PubMed ID: 12938640
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patient and family fact sheet. Current treatments for multiple sclerosis.
    Kernich CA
    Neurologist; 2005 Mar; 11(2):137-8. PubMed ID: 15733335
    [No Abstract]   [Full Text] [Related]  

  • 33. [Experience in copaxon treatment in Russia].
    Zavalishin IA; Peresedova AV; Stoĭda NI; Adarcheva LS; Zakharova MN; Niiazbekova AS; Askarova LSh; Rebrova OIu
    Zh Nevrol Psikhiatr Im S S Korsakova; 2005; 105(8):29-31. PubMed ID: 16180496
    [No Abstract]   [Full Text] [Related]  

  • 34. [Early immunomodulatory treatment of multiple sclerosis. Economic aspects].
    Czapliński A
    Neurol Neurochir Pol; 2001; 35(5):957-60. PubMed ID: 11873608
    [No Abstract]   [Full Text] [Related]  

  • 35. [Use of glatiramer acetate (Copaxone) in the treatment of patients with multiple sclerosis. Experience of the Moscow multiple sclerosis center].
    Demina TL; Davydovskaia MV; Lashch NIu; Popova NF; Khachanova NV; Zhuchenko TD
    Zh Nevrol Psikhiatr Im S S Korsakova; 2003; (Spec No 2):91-7. PubMed ID: 12938642
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The multiple sclerosis market.
    Huynh T
    Nat Rev Drug Discov; 2010 Oct; 9(10):759-60. PubMed ID: 20885402
    [No Abstract]   [Full Text] [Related]  

  • 37. [Pathogenesis and treatment of multiple sclerosis (state of the art in 2000)].
    Zavalishin IA; Zhuchenko TD; Peresedova AV
    Vestn Ross Akad Med Nauk; 2001; (7):18-22. PubMed ID: 11523422
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [State of antioxidant system in patients with multiple sclerosis during therapy].
    Smirnova LP; Krotenko NV; Grishko EV; Krotenko NM; Alifirova VM; Ivanova SA
    Biomed Khim; 2011; 57(6):661-70. PubMed ID: 22359923
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Multiple sclerosis: immunomodulators brake the appearance of "black holes"].
    MMW Fortschr Med; 2003 May; 145 Suppl 2():110. PubMed ID: 14579503
    [No Abstract]   [Full Text] [Related]  

  • 40. Editorial: the pitfalls of combination therapy.
    Vermersch P
    Int MS J; 2006 Nov; 13(3):75-6. PubMed ID: 17101074
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.